Human androgen receptor gene ligand-binding-domain mutations leading to disrupted interaction between the N- and C-terminal domains

J Jaaskelainen , A Deeb , JW Schwabe , NP Mongan
Journal of Molecular Endocrinology 36 ( 2) 361 -368

44
2006
Developmental aspects of androgen action.

I.A. Hughes , H.N. Lim , H. Martin , N.P. Mongan
Molecular and Cellular Endocrinology 185 ( 1) 33 -41

25
2001
A Fibromyxoid Stromal Response is Associated with Muscle Invasion in Canine Urothelial Carcinoma.

S. de Brot , L. Grau-Roma , C. Stirling-Stainsby , M. Dettwiler
Journal of Comparative Pathology 169 35 -46

3
2019
Retinoids: Nutritional, Cellular, and Pharmacological Roles of the Vitamin A Derivatives

S.S. Choong , J. Fulton , R.D. Emes , L. Yon
Reference Module in Biomedical Sciences

2015
Estrogen receptor-β expression and pharmacological targeting in bladder cancer.

ERIC C. KAUFFMAN , BRIAN D. ROBINSON , MARTIN DOWNES , KATARZYNA MARCINKIEWICZ
Oncology Reports 30 ( 1) 131 -138

24
2013
Evidence that luteinising hormone receptor polymorphisms may contribute to male undermasculinisation.

NP Mongan , IA Hughes , HN Lim
European Journal of Endocrinology 147 ( 1) 103 -107

12
2002
Steroid receptor coactivator-3 glutamine repeat polymorphism and the androgen insensitivity syndrome.

Nigel P Mongan , Jarmo Jääskeläinen , Sumit Bhattacharyya , Roberta M Leu
European Journal of Endocrinology 148 ( 2) 277 -279

7
2003
5
2001
2002
Molecular characterisation of canine osteosarcoma in high risk breeds

M Mestas , JN Jeyapalan , S Simpson , RD Emes

4th International Workshop on Development Endocrinology, Cambridge, September 2000

PE Mullis , JC Achermann , JJ Meeks , J Larry Jameson

Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level

NM Atallah , M Alsaleem , MS Toss , NP Mongan
British Journal of Cancer 129 ( 10) 1692 -1705

4
2023
Clinicopathological and functional evaluation reveal NBS1 as a predictor of platinum resistance in epithelial ovarian cancers. Biomedicines. 2021; 9 (1): 56

A Alblihy , ML Alabdullah , R Ali , M Algethami
s Note: MDPI stays neu-tral with regard to jurisdictional clai-ms in published maps and institutio-nal affiliations.

1
2021
Refining the definition of HER2 low class in invasive breast cancer

NM Atallah , MS Toss , AR Green , NP Mongan
JOURNAL OF PATHOLOGY 261 S9 -S9

2023
Differential response of HER2 positive breast cancer based on HER2 protein expression level

NM Atallah , MS Toss , M Al Saleem , AR Green
JOURNAL OF PATHOLOGY 261 S9 -S9

2023
Prognostic Significance of Cell Division Cycle 6 (CDC6) in Breast Cancer

Yousif Kariri , M Alsaleem , C Joseph , NP Mongan
JOURNAL OF PATHOLOGY 255 S50 -S50

2021
Over Expression of Retinoid X Receptor Gamma (RXRG) Predict Good Prognosis in Oestrogen Receptor Positive Breast Cancer

C Joseph , S Al-izzi , M Alsaleem , S Kurozumi
JOURNAL OF PATHOLOGY 249 S24 -S24

2019
Keratin 24 (KRT 24) Confers Poor Patient Outcome in Invasive Breast Cancer

Y Kariri , C Joseph , S Kurozumi , I Miligy
JOURNAL OF PATHOLOGY 249 S24 -S24

2019